Holen Sie sich die Stockscreener-App
1.60
5.26%
0.08
Vorhandelsmarkt:
1.60
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities - BioSpace
Quince Therapeutics announces closing of up to $22 million private placement of securities - MarketScreener
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities | QNCX Stock News - GuruFocus
June 2025's Promising Penny Stocks For Savvy Investors - simplywall.st
D. Boral Capital Reaffirms Buy Rating for Quince Therapeutics (NASDAQ:QNCX) - Defense World
Two Sigma Investments LP Takes $57,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics (QNCX) Analyst Rating Update: Buy Rating Mai - GuruFocus
Quince Therapeutics Raises $11.5M in Private Placement - TipRanks
Quince Therapeutics Announces Pricing of Up to $22 Million Priva - GuruFocus
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities - BioSpace
Quince Therapeutics (QNCX) Secures $11.5 Million Through New Sec - GuruFocus
Quince Therapeutics (QNCX) Secures $11.5M Through Private Placem - GuruFocus
Quince Therapeutics (QNCX) Secures $11.5 Million Through New Securities Agreement | QNCX Stock News - GuruFocus
Quince Therapeutics Prices $22 Million Private Placement of Shares, Warrants - marketscreener.com
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities | QNCX Stock News - GuruFocus
Quince Therapeutics Announces Pricing Of Up To $22 Mln Private Placement Of Securities - marketscreener.com
Quince Therapeutics stock soars after announcing $11.5 million private placement - Investing.com Nigeria
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Quince Therapeutics (QNCX) and Moderna (MRNA) - The Globe and Mail
Quince Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Transcript : Quince Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Shares Acquired by Northern Trust Corp - Defense World
Quince Therapeutics (QNCX) Stock Rating and Price Target Update - GuruFocus
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia - BioSpace
Quince Therapeutics Says Enrollment for Phase 3 Clinical Trial in Ataxia-Telangiectasia Exceeds 75% - marketscreener.com
Quince Therapeutics (QNCX) Phase 3 Trial Achieves Major Progress - GuruFocus
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NE - GuruFocus
Quince Therapeutics (QNCX) Phase 3 Trial Achieves Major Progress in Enrollment | QNCX Stock News - GuruFocus
Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 42.9% in May - Defense World
FY2025 Earnings Forecast for TSE:WEE Issued By Roth Capital - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
HC Wainwright Has Positive Estimate for ORKA Q2 Earnings - Defense World
Q2 EPS Estimate for Century Therapeutics Raised by Analyst - Defense World
Rani Therapeutics (NASDAQ:RANI) Stock Price Up 7% – Here’s What Happened - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) and Quince Therapeutics (NASDAQ:QNCX) Head to Head Comparison - Defense World
Brookline Capital Management Forecasts QNCX Q2 Earnings - Defense World
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026 (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics Reports Q1 2025 Results and Strategic Updates - TipRanks
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - BioSpace
Quince Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quince Therapeutics, Inc. SEC 10-Q Report - TradingView
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results | QNCX Stock News - GuruFocus
QNCXQuince Latest Stock News & Market Updates - Stock Titan
Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Recommendation of “Buy” from Analysts - Defense World
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Confe - GuruFocus
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Conference - GuruFocus
Geode Capital Management LLC Has $703,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Citizens Life Sciences Conference - BioSpace
Quince Therapeutics Inc (QNCX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Ratios Uncovered: Breaking Down Quince Therapeutics Inc (QNCX)’s Trailing Twelve Months Metrics - DWinneX
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):